Antibody Discovery Market Size, Trends and Forecasts

Antibody Discovery Market Size, Trends and Forecasts

Industry Introduction

The antibody discovery industry is witnessing robust expansion driven by advances in biotherapeutics and precision medicine. Recent market research reveals unprecedented innovation in screening technologies, accelerating business growth and reshaping industry share distributions. Insights into late-stage pipelines provide granular market insights and highlight evolving market dynamics across pharmaceutical and biotechnology firms.

Market Size and Overview

The Global Antibody Discovery Market size is estimated to be valued at USD 3.15 Bn in 2025 and is expected to reach USD 7.18 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 12% from 2025 to 2032.

In 2024, industry size surged as demand for novel monoclonal therapies rose by 8%, boosting market revenue and reinforcing the market forecast outlook. The Antibody Discovery Market report underscores growing research investments, technological breakthroughs, and expanding bioproduction capabilities that are shaping market trends and opportunities. The Antibody Discovery Market share is concentrated in high-throughput platforms like phage display, reflecting industry trends.

Core Market Segments

Technology Platforms: Sub-segments include Phage Display, Hybridoma, Transgenic Animal Models, Single B-Cell Screening and Yeast Display. Phage Display remains dominant with revenue exceeding USD 1.2 Bn in 2025, while Single B-Cell Screening is the fastest-growing, recording a 30% increase in service contracts in 2024. BiotechX leveraged Single B-Cell Screening in early 2025 to reduce candidate lead times by 25%, illustrating strong market growth strategies.

End Users: Key categories are Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs) and Academic & Research Institutes. Pharmaceutical Companies led in project volume during 2024, whereas CRO partnerships jumped 18%, driven by outsourcing trends and broader market opportunities.

Applications: Therapeutic Antibody Discovery, Diagnostic Development and Research Reagents form the core applications. Therapeutics garnered the largest R&D spend, but Diagnostic Development grew fastest, up 22% YoY in 2025 as point-of-care testing proliferated, highlighting emerging market segments.

Market Drivers

Rising demand for personalized therapies is the principal market driver propelling market growth through 2024–2025. The global chronic disease burden rose 6% in 2024, prompting regulators to fast-track monoclonal approvals by 35% under accelerated pathways—resulting in 43 new mAb approvals in 2025. However, market restraints such as high capital investment and stringent regulatory hurdles temper rapid scale-up. These dynamics underscore evolving market drivers and market challenges that shape strategic investments.

Segment Analysis

Focusing on the Technology Platform segment, Phage Display secured dominant status with Antibody Discovery Market revenue surpassing USD 1.2 Bn in 2025. Single B-Cell Screening emerged as the fastest-growing sub-segment, with revenue climbing from USD 200 Mn in 2024 to USD 260 Mn in 2025. A 2024 Genmab case study showed that adopting Single B-Cell Screening accelerated candidate nominations by 40%, exemplifying effective market growth strategies and market analysis in action.

Consumer Behaviour Insights

Between 2024 and 2025, end users exhibited distinct behavioural shifts. First, 68% of biotech firms adopted cloud-based platforms for digital-first R&D workflows, per the 2025 BioIndustry Association survey. Second, pricing sensitivity rose: 72% of CROs negotiated volume-based agreements, according to a 2024 feedback report. Third, customization preferences intensified, with 45% of pharma buyers favoring bespoke AI-driven epitope mapping services. These Antibody Discovery Market trends reflect a demand for flexible, integrated discovery packages and enhanced market opportunities for specialized providers.

Key Players

Prominent market companies include WuXi Biologics, GenScript, Genmab, Harbour BioMed, ImmunoPrecise, AbCellera, Bio-Rad Laboratories, Merck KGaA, Thermo Fisher Scientific, Agilent Technologies, Bio-Techne and AstraZeneca. In 2024, Thermo Fisher launched its LunaFlex high-throughput platform, boosting screening throughput by 25%. Bio-Techne expanded its Singapore antibody engineering facility in 2025, adding capacity for 1,000 hybridoma projects annually. AbCellera’s entry into the Asia-Pacific region in Q3 2024 secured three major licensing deals by year-end, underscoring successful market expansion strategies.

Key Winning Strategies

In 2025, GenScript rolled out an AI-driven lead optimization engine that cut discovery timelines by 40%, setting a new benchmark in market growth strategies. WuXi Biologics introduced an end-to-end integrated service model in 2024, delivering a 30% faster transition from discovery to IND filing and attracting multiple top-tier pharma partnerships. AbCellera’s 2025 investment in microfluidics-based single-cell screening increased throughput by 50%, resulting in three new licensing agreements and demonstrating impactful, differentiated approaches to antibody discovery.

FAQs

1. Who are the dominant players in the Antibody Discovery Market?
Key players include WuXi Biologics, GenScript, Genmab, Harbour BioMed, ImmunoPrecise and AbCellera, each excelling in specific platforms like phage display and single B-cell screening.

2. What will be the size of the Antibody Discovery Market in the coming years?
The market is projected to grow from USD 3.15 Bn in 2025 to USD 7.18 Bn by 2032, at a CAGR of 12%.

3. Which end-user segment has the largest growth opportunity?
Contract Research Organizations (CROs) offer the fastest growth, with partnership agreements rising 18% in 2024 due to increased outsourcing of discovery services.

4. How will Antibody Discovery Market trends evolve over the next five years?
Expect deeper AI integration, broader adoption of single-cell platforms and expansion of diagnostic applications, driving sustained market revenue growth.

5. What are the primary challenges in the Antibody Discovery Market?
Challenges include high R&D costs, complex regulatory pathways and scarcity of specialized expertise, which act as market restraints.

6. What go-to-market strategies are commonly adopted in the Antibody Discovery Market?
Strategies often involve end-to-end integrated service offerings, AI-powered optimization tools and strategic regional collaborations to broaden market scope.

‣ Get More Insights On: Antibody Discovery Market

‣ Get this Report in Japanese Language: 抗体発見市場

‣ Get this Report in Korean Language: 항체발견시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)